CAPTRUST Financial Advisors
KPTI icon

CAPTRUST Financial Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67
Closed -$5K – 3119
2022
Q2 		$5K Hold
67
– – ﹤0.01% 4095
2022
Q1 		$7K Hold
67
– – ﹤0.01% 3970
2021
Q4 		$6K Sell
67
-8
-11% -$797 ﹤0.01% 3990
2021
Q3 		$7K Sell
75
-221
-75% -$22.9K ﹤0.01% 3809
2021
Q2 		$46K Buy
296
+63
+27% +$9.14K ﹤0.01% 2566
2021
Q1 		$37K Hold
233
– – ﹤0.01% 2619
2020
Q4 		$54K Buy
233
+200
+606% +$46.3K ﹤0.01% 1793
2020
Q3 		$7K Hold
33
– – ﹤0.01% 2425
2020
Q2 		$10K Buy
+33
New +$9.76K ﹤0.01% 2182

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

CAPTRUST Financial Advisors's KPTI Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 67 shares — an estimated $5K sold.

CAPTRUST Financial Advisors first reported a position in KPTI in Q2 2020 and held it in 9 quarters. The position peaked at $54K in Q4 2020. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 67 Karyopharm Therapeutics shares in Q3 2022, an estimated $5K.
  • CAPTRUST Financial Advisors first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 9 quarters.
  • CAPTRUST Financial Advisors's Karyopharm Therapeutics position peaked at $54K in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.